120 related articles for article (PubMed ID: 14505653)
1. Pyrimido[1,2-b]-1,2,4,5-tetrazin-6-ones as HCMV protease inhibitors: a new class of heterocycles with flavin-like redox properties.
Di Grandi MJ; Curran KJ; Baum EZ; Bebernitz G; Ellestad GA; Ding WD; Lang SA; Rossi M; Bloom JD
Bioorg Med Chem Lett; 2003 Oct; 13(20):3483-6. PubMed ID: 14505653
[TBL] [Abstract][Full Text] [Related]
2. Flavins inhibit human cytomegalovirus UL80 protease via disulfide bond formation.
Baum EZ; Ding WD; Siegel MM; Hulmes J; Bebernitz GA; Sridharan L; Tabei K; Krishnamurthy G; Carofiglio T; Groves JT; Bloom JD; DiGrandi M; Bradley M; Ellestad G; Seddon AP; Gluzman Y
Biochemistry; 1996 May; 35(18):5847-55. PubMed ID: 8639546
[TBL] [Abstract][Full Text] [Related]
3. The herpesvirus protease: mechanistic studies and discovery of inhibitors of the human cytomegalovirus protease.
Flynn DL; Becker DP; Dilworth VM; Highkin MK; Hippenmeyer PJ; Houseman KA; Levine LM; Li M; Moormann AE; Rankin A; Toth MV; Villamil CI; Wittwer AJ; Holwerda BC
Drug Des Discov; 1997 May; 15(1):3-15. PubMed ID: 9332827
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and antiviral activity of monobactams inhibiting the human cytomegalovirus protease.
Ogilvie WW; Yoakim C; Dô F; Haché B; Lagacé L; Naud J; O'Meara JA; Déziel R
Bioorg Med Chem; 1999 Aug; 7(8):1521-31. PubMed ID: 10482444
[TBL] [Abstract][Full Text] [Related]
5. In vitro proteolytic activity and active-site identification of the human cytomegalovirus protease.
Stevens JT; Mapelli C; Tsao J; Hail M; O'Boyle D; Weinheimer SP; Diianni CL
Eur J Biochem; 1994 Dec; 226(2):361-7. PubMed ID: 8001553
[TBL] [Abstract][Full Text] [Related]
6. Characterization of a soluble stable human cytomegalovirus protease and inhibition by M-site peptide mimics.
LaFemina RL; Bakshi K; Long WJ; Pramanik B; Veloski CA; Wolanski BS; Marcy AI; Hazuda DJ
J Virol; 1996 Jul; 70(7):4819-24. PubMed ID: 8676515
[TBL] [Abstract][Full Text] [Related]
7. Evidence of a conformational change in the human cytomegalovirus protease upon binding of peptidyl-activated carbonyl inhibitors.
Bonneau PR; Grand-Maître C; Greenwood DJ; Lagacé L; LaPlante SR; Massariol MJ; Ogilvie WW; O'Meara JA; Kawai SH
Biochemistry; 1997 Oct; 36(41):12644-52. PubMed ID: 9376371
[TBL] [Abstract][Full Text] [Related]
8. Design and synthesis of pyrrolidine-5,5'-trans-lactams (5-oxo-hexahydropyrrolo[3,2-b]pyrroles) as novel mechanism-based inhibitors of human cytomegalovirus protease. 4. Antiviral activity and plasma stability.
Borthwick AD; Davies DE; Ertl PF; Exall AM; Haley TM; Hart GJ; Jackson DL; Parry NR; Patikis A; Trivedi N; Weingarten GG; Woolven JM
J Med Chem; 2003 Oct; 46(21):4428-49. PubMed ID: 14521407
[TBL] [Abstract][Full Text] [Related]
9. Selective nonpeptidic inhibitors of herpes simplex virus type 1 and human cytomegalovirus proteases.
Matsumoto M; Misawa S; Chiba N; Takaku H; Hayashi H
Biol Pharm Bull; 2001 Mar; 24(3):236-41. PubMed ID: 11256477
[TBL] [Abstract][Full Text] [Related]
10. Pyrrolidine-5,5-trans-lactams as novel mechanism-based inhibitors of human cytomegalovirus protease. Part 3: potency and plasma stability.
Borthwick AD; Exall AM; Haley TM; Jackson DL; Mason AM; Weingarten GG
Bioorg Med Chem Lett; 2002 Jul; 12(13):1719-22. PubMed ID: 12067545
[TBL] [Abstract][Full Text] [Related]
11. Whence flavins? Redox-active ribonucleotides link metabolism and genome repair to the RNA world.
Nguyen KV; Burrows CJ
Acc Chem Res; 2012 Dec; 45(12):2151-9. PubMed ID: 23054469
[TBL] [Abstract][Full Text] [Related]
12. From 1-acyl-beta-lactam human cytomegalovirus protease inhibitors to 1-benzyloxycarbonylazetidines with improved antiviral activity. A straightforward approach to convert covalent to noncovalent inhibitors.
Gerona-Navarro G; Pérez de Vega MJ; García-López MT; Andrei G; Snoeck R; De Clercq E; Balzarini J; González-Muñiz R
J Med Chem; 2005 Apr; 48(7):2612-21. PubMed ID: 15801851
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of human cytomegalovirus UL80 protease by specific intramolecular disulfide bond formation.
Baum EZ; Siegel MM; Bebernitz GA; Hulmes JD; Sridharan L; Sun L; Tabei K; Johnston SH; Wildey MJ; Nygaard J; Jones TR; Gluzman Y
Biochemistry; 1996 May; 35(18):5838-46. PubMed ID: 8639545
[TBL] [Abstract][Full Text] [Related]
14. Design of fluorogenic peptide substrates for human cytomegalovirus protease based on structure-activity relationship studies.
Bonneau PR; Plouffe C; Pelletier A; Wernic D; Poupart MA
Anal Biochem; 1998 Jan; 255(1):59-65. PubMed ID: 9448842
[TBL] [Abstract][Full Text] [Related]
15. Novel yeast cell-based assay to screen for inhibitors of human cytomegalovirus protease in a high-throughput format.
Cottier V; Barberis A; Lüthi U
Antimicrob Agents Chemother; 2006 Feb; 50(2):565-71. PubMed ID: 16436711
[TBL] [Abstract][Full Text] [Related]
16. Dimerization of the human cytomegalovirus protease: kinetic and biochemical characterization of the catalytic homodimer.
Margosiak SA; Vanderpool DL; Sisson W; Pinko C; Kan CC
Biochemistry; 1996 Apr; 35(16):5300-7. PubMed ID: 8611517
[TBL] [Abstract][Full Text] [Related]
17. Design and synthesis of pyrrolidine-5,5-trans-lactams (5-oxohexahydropyrrolo[3,2-b]pyrroles) as novel mechanism-based inhibitors of human cytomegalovirus protease. 2. Potency and chirality.
Borthwick AD; Crame AJ; Ertl PF; Exall AM; Haley TM; Hart GJ; Mason AM; Pennell AM; Singh OM; Weingarten GG; Woolven JM
J Med Chem; 2002 Jan; 45(1):1-18. PubMed ID: 11754575
[TBL] [Abstract][Full Text] [Related]
18. Investigation of the induced-fit mechanism and catalytic activity of the human cytomegalovirus protease homodimer via molecular dynamics simulations.
de Oliveira CA; Guimarães CR; Barreiro G; de Alencastro RB
Proteins; 2003 Sep; 52(4):483-91. PubMed ID: 12910449
[TBL] [Abstract][Full Text] [Related]
19. Peptidomimetic inhibitors of the human cytomegalovirus protease.
Ogilvie W; Bailey M; Poupart MA; Abraham A; Bhavsar A; Bonneau P; Bordeleau J; Bousquet Y; Chabot C; Duceppe JS; Fazal G; Goulet S; Grand-Maître C; Guse I; Halmos T; Lavallée P; Leach M; Malenfant E; O'Meara J; Plante R; Plouffe C; Poirier M; Soucy F; Yoakim C; Déziel R
J Med Chem; 1997 Dec; 40(25):4113-35. PubMed ID: 9406601
[TBL] [Abstract][Full Text] [Related]
20. Investigation of the covalent modification of the catalytic triad of human cytomegalovirus protease by pseudo-reversible beta-lactam inhibitors and a peptide chloromethylketone.
Haley TM; Angier SJ; Borthwick AD; Montgomery DS; Purvis IJ; Smart DH; Bessant C; Van Wely C; Hart GJ
J Mass Spectrom; 1998 Dec; 33(12):1246-55. PubMed ID: 9875526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
